Reuters logo
BRIEF-Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab
2017年9月27日 / 下午1点19分 / 25 天前

BRIEF-Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab

Sept 27 (Reuters) - Immune Pharmaceuticals Inc

* Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab in bullous pemphigoid

* Immune Pharmaceuticals Inc - ‍Results from three new subjects confirm and extend previous findings​

* Immune Pharmaceuticals Inc says ‍bertilimumab was well tolerated in all six subjects and no serious adverse events were reported​

* Immune Pharmaceuticals Inc - ‍Results from six subjects​ had no serious adverse events

* Immune Pharmaceuticals Inc - ‍Will continue to enroll subjects into the phase 2 open label BP trial, which has target enrollment of 12 to 15 patients​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below